Stock NDYN VININGS HOLDINGS INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

News Vinings Holdings Inc. Other OTC

Equities

NDYN

US92744A1051

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Coeptis Therapeutics Dr. Colleen Delaney to Present at Allogeneic Cell Therapies Summit 6th Annual Meeting
AQ
Coeptis Therapeutics' Dr. Colleen Delaney to Present at Allogeneic Cell Therapies Summit 6th Annual Meeting
PR
Coeptis Therapeutics Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Coeptis Therapeutics to Present its Universal Allogeneic SNAP-CAR NK Cell Therapy at the ISCT 2024
PR
Coeptis Therapeutics Announces Poster Data Presentation at American Society of Gene and Cell Therapy 27th Annual Meeting
AQ
Coeptis Therapeutics Congratulates Alexander Deiters, Professor at the University of Pittsburgh, on receiving the 2024 Chancellor s Distinguished Research Award
AQ
Coeptis Therapeutics Congratulates Alexander Deiters, Professor at the University of Pittsburgh, on Receiving the 2024 Chancellor's Distinguished Research Award
PR
Coeptis Therapeutics Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Coeptis Therapeutics Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for SNAP-CAR T and SNAP-CAR NK
AQ
Coeptis Therapeutics Holdings, Inc. Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for SNAP-CAR T and SNAP-CAR NK
CI
Coeptis Therapeutics to Pursue Phase 2 Program Using Proprietary First-in-Class Allogeneic NK Cell Therapy for the Treatment of Viral Infections
PR
Coeptis Therapeutics to Pursue Phase 2 Program Using Proprietary First-In-Class Allogeneic NK Cell Therapy for the Treatment of Viral Infections
CI
Coeptis Therapeutics President and CEO Issues Letter to Shareholders Highlighting 2023 Accomplishments and Outlook for 2024
PR
Coeptis Therapeutics to Present at the Emerging Growth Conference
PR
Coeptis Therapeutics Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Coeptis Therapeutics Holdings, Inc. announced that it has received $2 million in funding
CI
Coeptis Therapeutics Announces Research Demonstrating the Potential of SNAP-CAR T-cells to Reduce Tumor Burden and Growth in HER2 and CD20 Expressing Cancers Will be Presented at SITC 2023
PR
Coeptis Therapeutics Announces $2 Million Private Placement
PR
Coeptis Therapeutics Holdings, Inc. announced that it expects to receive $2 million in funding
CI
Coeptis Therapeutics : Private Placement - Form 8-K
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. COEP Stock
  4. NDYN Stock
  5. News Vinings Holdings Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW